{"id":"W2122348159","doi":"10.1016/s0264-410x(02)00087-7","title":"Therapeutic vaccination in primary HIV infection, the Quest1Quest Core Group and Research Team: D. Cooper, Australia; B. Hoen, France; S. Kinloch, UK; A. Phillips, UK; C. Tsoukas, Canada; J. Andersson, Sweden; F. Lampe, UK; B. Autran, France; G. Janossy, UK; V. Miller, Germany; Z. Racz, Germany; R. Sekaly, Canada; clinicians in more than 20 recruiting centres and the supporting team of GlaxoSmithKline: V. Mallet, S. Turkish, S. Fortes, C. Python, M. Haberl and Li-Ean Goh, Quest project leader UK. Industry collaborators—main sponsor: GlaxoSmithKline, Hugh Mc Dade; Roche Molecular Systems: B. Dale, A. Capt; Immune Response Corporation: R. Moss, J. Dively.1 trial","year":2002,"lang":"en","type":"article","venue":"Vaccine","topic":"HIV Research and Treatment","field":"Immunology and Microbiology","cited_by":9,"is_retracted":false,"has_abstract":false,"ca_institutions":"","funders":"","keywords":"Vaccination; Immunology; Immune system; Human immunodeficiency virus (HIV); Medicine; Antigen; AIDS Vaccines; Vaccine efficacy; Immunotherapy; Virology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001728537,0.0003981548,0.0007982323,0.0001594079,0.0006495376,0.0006335181,0.0003029656,0.001301278,0.02883418],"category_scores_gemma":[0.001765123,0.0001920124,0.000574804,0.0001692057,0.0003891707,0.0005206019,0.0003538857,0.001690695,0.003085176],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006020651,"about_ca_system_score_gemma":0.001048434,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000746963,"about_ca_topic_score_gemma":0.001908307,"domain_scores_codex":[0.9994705,0.0003267756,0.00002204922,0.0000558084,0.00003984668,0.00008509343],"domain_scores_gemma":[0.9990735,0.0002507156,0.00007302207,0.00008154851,0.00007706528,0.0004440862],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.1551685,0.00938158,0.0149814,0.003684356,0.000693193,0.00047926,0.0004374328,0.0007291427,0.006685058,0.003266931,0.1597385,0.6447547],"study_design_scores_gemma":[0.2290762,0.2581992,0.1232362,0.002920272,0.00103802,0.002811974,0.0003002286,0.001924362,0.004849845,0.004351556,0.3712344,0.00005775961],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6908617,0.1066974,0.003082199,0.01817094,0.003715658,0.006428104,0.009647836,0.0003188826,0.1610773],"genre_scores_gemma":[0.8987781,0.01455444,0.002586511,0.00745887,0.002041084,0.003860887,0.005135804,0.00005811969,0.06552622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02883418,"threshold_uncertainty_score":0.09645998,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03328373061977238,"score_gpt":0.3029360584065439,"score_spread":0.2696523277867715,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}